BioSpace News Archive

Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today the purchase of the neurology portfolio from Eton Pharmaceuticals.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch + Lomb, a leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA ® (latanoprostene bunod ophthalmic solution), 0.024%, has received approval from the Ministry of Food and Drug Safety in South Korea

Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer.

Lassen Therapeutics , a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia.

- Total FY revenues of $2.67 billion (+24% y/y); total FY product and royalty revenues increased 18% to $2.46 billion; three new FDA approvals in 2020 - Jakafi ® (ruxolitinib) FY revenue increased to $1.94 billion (+15% y/y); Jakafi ® guidance range of $2.125 to $2.20 billion for 2021 - Successful launches of Monjuvi ® (tafasitamab-cxix) and Pemazyre ® (pemigatinib) in the U.S.

Collaboration with Cleveland Clinic to support creation of novel next-generation mini-gene platform to pursue monogenic diseases not addressable by conventional AAV gene therapy technologies Collaboration with UT Southwestern Gene Therapy Program to develop new constructs incorporating novel mini-gene payloads, aligned with previously established partnership with Taysha

Antev Ltd , a late clinical-stage drug development company advancing the drug teverelix to treat prostate cancer and related indications, today announces the appointment of Amit Kohli as Chief Executive Officer

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO™ (berotralstat) will be presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held virtually from February 26-March 1, 2021.

Brooklyn ImmunoTherapeutics , a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the initiation of an open-label Phase 2 clinical trial of IRX-2 in combination with pembrolizumab (Keytruda ® ) and chemotherapy in triple negative breast cancer (TNBC). The trial will be conducted at the Providence Cancer Institute in Portland, Oreg

To Support New Product Development of Custom Skin Fixation and Topical Solutions for Wound Care, Wearable Medical Devices and Healthcare Consumer Markets